Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression.
brain volumes
depression
inferior frontal gyrus
ketamine
magnetic resonance imaging
major depressive disorder
post-traumatic stress disorder
structural alterations
Journal
Chronic stress (Thousand Oaks, Calif.)
ISSN: 2470-5470
Titre abrégé: Chronic Stress (Thousand Oaks)
Pays: United States
ID NLM: 101701229
Informations de publication
Date de publication:
Historique:
received:
20
10
2020
accepted:
20
11
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Ketamine is a novel fast-acting antidepressant. Acute ketamine treatment can reverse microstructure deficits and normalize functional alterations in the brain, but little is known about the impacts of ketamine on brain volumes in individuals with depression. We used 3 T magnetic resonance imaging (MRI) and tensorbased morphological methods to investigate the regional volume differences for 29 healthy control (HC) subjects and 21 subjects with major depressive disorder (MDD), including 10 subjects with comorbid post-traumatic stress disorder (PTSD). All the subjects participated in MRI scanning before and 24 h post intravenous ketamine infusion. The effects of acute ketamine administration on HC, MDD, and MDD/PTSD groups were examined separately by whole-brain voxel-wise t-tests. Our data showed smaller volume of inferior frontal gyrus (IFG, opercular part) in MDD and MDD/PTSD subjects compared to HC, and a significant correlation between opercular IFG volume and depressive severity in MDD subjects only. Ketamine administration normalized the structural alterations of opercular IFG in both MDD and MDD/PTSD groups, and significantly improved depressive and PTSD symptoms. Twenty-four hours after a single ketamine infusion, there were two clusters of voxels with volume changes in MDD subjects, including significantly increased volumes of opercular IFG. No significant structural alterations were found in the MDD/PTSD or HC groups. These findings provide direct evidence that acute ketamine administration can normalize structural alterations associated with depression and highlight the importance of IFG in the guidance of future therapeutic targets.
Sections du résumé
BACKGROUND
BACKGROUND
Ketamine is a novel fast-acting antidepressant. Acute ketamine treatment can reverse microstructure deficits and normalize functional alterations in the brain, but little is known about the impacts of ketamine on brain volumes in individuals with depression.
METHODS
METHODS
We used 3 T magnetic resonance imaging (MRI) and tensorbased morphological methods to investigate the regional volume differences for 29 healthy control (HC) subjects and 21 subjects with major depressive disorder (MDD), including 10 subjects with comorbid post-traumatic stress disorder (PTSD). All the subjects participated in MRI scanning before and 24 h post intravenous ketamine infusion. The effects of acute ketamine administration on HC, MDD, and MDD/PTSD groups were examined separately by whole-brain voxel-wise t-tests.
RESULTS
RESULTS
Our data showed smaller volume of inferior frontal gyrus (IFG, opercular part) in MDD and MDD/PTSD subjects compared to HC, and a significant correlation between opercular IFG volume and depressive severity in MDD subjects only. Ketamine administration normalized the structural alterations of opercular IFG in both MDD and MDD/PTSD groups, and significantly improved depressive and PTSD symptoms. Twenty-four hours after a single ketamine infusion, there were two clusters of voxels with volume changes in MDD subjects, including significantly increased volumes of opercular IFG. No significant structural alterations were found in the MDD/PTSD or HC groups.
CONCLUSION
CONCLUSIONS
These findings provide direct evidence that acute ketamine administration can normalize structural alterations associated with depression and highlight the importance of IFG in the guidance of future therapeutic targets.
Identifiants
pubmed: 33426409
doi: 10.1177/2470547020980681
pii: 10.1177_2470547020980681
pmc: PMC7758564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2470547020980681Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Biol Psychiatry. 2012 Oct 1;72(7):588-94
pubmed: 22704059
Neuroimage. 2016 Aug 1;136:26-36
pubmed: 27188219
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109676
pubmed: 31226395
Biol Psychol. 2015 Jul;109:184-91
pubmed: 26073417
Harv Rev Psychiatry. 2018 Nov/Dec;26(6):320-339
pubmed: 29465479
J Affect Disord. 2012 Apr;138(1-2):9-18
pubmed: 21511342
Neuropsychopharmacology. 2020 May;45(6):1026-1033
pubmed: 31995813
Mol Psychiatry. 2018 Apr;23(4):801-811
pubmed: 29532791
Biol Psychiatry. 2017 Sep 1;82(5):339-350
pubmed: 28318491
Neuropsychopharmacology. 2020 May;45(6):990-997
pubmed: 32092760
Hum Brain Mapp. 2016 Dec;37(12):4472-4486
pubmed: 27510944
J Neurol. 2015 May;262(5):1255-65
pubmed: 25794861
J Affect Disord. 2016 Jan 15;190:836-841
pubmed: 26630613
Biol Psychiatry. 2013 Aug 15;74(4):250-6
pubmed: 22840761
Curr Biol. 2019 Jan 21;29(2):R59-R62
pubmed: 30668950
Brain. 2016 Dec;139(Pt 12):3296-3309
pubmed: 27742666
Biol Psychiatry. 2016 Feb 15;79(4):293-302
pubmed: 25891219
Neuropsychopharmacology. 2018 Apr;43(5):1119-1127
pubmed: 28944772
Neuropsychopharmacology. 2018 Feb;43(3):546-554
pubmed: 29039414
Neuron. 2019 Mar 6;101(5):774-778
pubmed: 30844397
Mol Psychiatry. 2017 Jun;22(6):900-909
pubmed: 27137745
Curr Opin Pharmacol. 2015 Feb;20:35-9
pubmed: 25462290
Neurosci Lett. 2015 Aug 5;601:20-9
pubmed: 25582786
Neuropsychopharmacology. 2017 Jul;42(8):1739-1746
pubmed: 28272497
Neurosci Biobehav Rev. 2016 Jan;60:43-50
pubmed: 26592799
Curr Biol. 2018 Dec 17;28(24):3893-3902.e4
pubmed: 30503621
Neuroimage. 2011 Feb 14;54(4):2643-51
pubmed: 21073959
Insight J. 2006;2006:209
pubmed: 25364771
Neuropsychopharmacology. 2017 May;42(6):1210-1219
pubmed: 27604566
JAMA Psychiatry. 2020 Feb 1;77(2):172-179
pubmed: 31664439
Psychol Med. 2014 Oct;44(14):2927-37
pubmed: 25065859
Neuropsychopharmacology. 2020 Mar;45(4):703-712
pubmed: 31694045
Neuropsychopharmacology. 2020 May;45(6):975-981
pubmed: 31896116
Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jan;6(1):50-58
pubmed: 32855106
Neuropsychopharmacology. 2018 Sep;43(10):2154-2160
pubmed: 29977074
Mol Psychiatry. 2020 Jul;25(7):1511-1525
pubmed: 31471575
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Transl Psychiatry. 2018 Dec 10;8(1):272
pubmed: 30531859
Transl Psychiatry. 2019 Nov 7;9(1):280
pubmed: 31699965
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
Brain. 2016 Apr;139(Pt 4):1295-309
pubmed: 26811252
Mol Psychiatry. 2013 Dec;18(12):1265-72
pubmed: 23128153
Nat Commun. 2019 Apr 4;10(1):1529
pubmed: 30948709
J Neurosci. 2016 Aug 31;36(35):9217-26
pubmed: 27581461
Biol Psychiatry. 2019 Nov 15;86(10):759-768
pubmed: 31443934
Am J Psychiatry. 2018 Apr 1;175(4):327-335
pubmed: 29202655
Neuroimage Clin. 2016 May 14;11:658-666
pubmed: 27222797
Soc Cogn Affect Neurosci. 2020 Jan 30;15(1):75-86
pubmed: 31993660
Neuroimage. 2020 Feb 1;206:116189
pubmed: 31521825
Mol Psychiatry. 2020 Jul;25(7):1550-1558
pubmed: 31758093
JAMA. 2017 Apr 18;317(15):1517
pubmed: 28418490
Neuroimage. 2017 Feb 15;147:198-203
pubmed: 27986606
J Affect Disord. 2017 Mar 01;210:72-81
pubmed: 28013125
Am J Psychiatry. 2018 Feb 01;175(2):150-158
pubmed: 28969441
Mol Psychiatry. 2018 Apr;23(4):812-823
pubmed: 29158584
Acta Neuropsychiatr. 2019 Oct;31(5):252-257
pubmed: 31234950
Biol Psychiatry. 2014 Dec 15;76(12):970-6
pubmed: 24821196
Neuropsychopharmacology. 2020 Jan;45(2):283-291
pubmed: 31610545